

Glycosaminoglycans: Definition and Structure

Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long, linear **polysaccharides** composed of repeating disaccharide units ¹. Each disaccharide contains an **amino sugar** (N-acetylglucosamine or N-acetylgalactosamine) and a **hexose or hexuronic acid** (usually glucuronic or iduronic acid) ² ¹. In aqueous solution GAGs carry dense negative charge (due to carboxylate and sulfate groups) and thus **attract water**, giving tissues cushioning and hydration properties ³ ¹. The specific monosaccharide composition and sulfation pattern define each GAG's chemical identity. For example, **hyaluronan (HA)** is the simplest GAG: an unsulfated polymer of alternating β -1,3 and β -1,4 linked D-glucuronic acid and N-acetyl-D-glucosamine ⁴ ⁵. Other GAGs are sulfated on various hydroxyl or amino groups, creating highly anionic chains. Four major families are defined by their disaccharides: **heparin/heparan sulfate (HP/HS)**, **chondroitin/dermatan sulfate (CS/DS)**, **keratan sulfate (KS)**, and **hyaluronan (HA)** ¹ ⁵. Each has a characteristic disaccharide (see figure) and distinct linkage geometry and modifications ⁶ ⁷.

Figure: Chemical structure of hyaluronan (HA), the simplest GAG. HA consists of repeating D-glucuronic acid–D-N-acetylglucosamine disaccharides (shown). Other GAGs have additional sulfates or epimerization.

Types of GAGs

Hyaluronic Acid (HA)

HA is a non-sulfated GAG made of repeating β -1,3/ β -1,4 linked D-glucuronic acid and N-acetyl-D-glucosamine ⁴ ⁵. Unlike other GAGs, HA is synthesized at the plasma membrane (not in the Golgi) and secreted as a high-molecular-weight polymer ⁸ ⁹. It forms viscous, gel-like matrices in connective tissues and joint fluids, providing **shock absorption, hydration and lubrication**. HA also helps organize collagen fibrils and regulates cell migration by forming provisional matrices (e.g. during wound healing) ¹⁰ ¹¹.

Heparin and Heparan Sulfate (HP/HS)

Heparan sulfate (HS) and its highly sulfated analogue heparin are composed of repeating **α -1,4 linked** disaccharides of glucosamine (GlcN) and uronic acid ⁶. In HS the uronic acid is mainly D-glucuronic acid, whereas heparin is enriched in L-iduronic acid ⁶. Both carry extensive N- and O-sulfates, giving the chains strong negative charge. Heparan sulfate chains are covalently attached to core proteins (e.g. syndecans, glypicans) via a Ser-O-tetrasaccharide linker (Xyl–Gal–Gal–GlcA) ¹² ⁶. Heparin, found in mast cell granules, differs mostly in having higher sulfation and more iduronic acid. In humans, HS on cell surfaces and in the extracellular matrix binds growth factors (FGFs, VEGF, etc.), chemokines, and morphogens, modulating signaling. Clinically, pharmaceutical heparin (porcine mucosa derived) is a potent **anticoagulant** (potentiating antithrombin III) used in medicine ¹³. Heparin/HS also protect proteins from proteolysis and regulate lipid metabolism.

Figure: Chemical structure of heparan sulfate (one repeating disaccharide unit shown). Heparan sulfate (HS) contains N-acetyl- or N-sulfated glucosamine (GlcN) linked to a uronic acid (glucuronic or iduronic acid), with multiple sulfation points. Heparin is a closely related, highly sulfated form. Each disaccharide is linked via α -(1→4) bonds.

Chondroitin and Dermatan Sulfate (CS/DS)

Chondroitin sulfates are polymers of **β -1,3/ β -1,4 linked** repeats of D-glucuronic acid and N-acetylgalactosamine ⁷. Dermatan sulfate (also called chondroitin sulfate B) differs only in having L-iduronic acid (formed by C5-epimerization of glucuronic acid) in place of some glucuronic acids ⁷. In both CS and DS, the GalNAc is often sulfated at C-4 or C-6 (e.g. CS-A: 4-O-sulfate, CS-C: 6-O-sulfate). These GAGs are attached via the common Xyl-Gal-Gal-GlcA linker to core proteins (e.g. aggrecan in cartilage, decorin/biglycan) ¹² ⁷. CS/DS provide **structural support and resilience** in cartilage, tendons and skin by retaining water and spacing collagen fibers. They also interact with cytokines and growth factors; for example, DS from mast cells can enhance anti-thrombin activity.

Figure: Chemical structure of chondroitin sulfate (a representative disaccharide). Chondroitin sulfate (CS) is made of β -(1→4) linked D-glucuronic acid–N-acetyl-D-galactosamine disaccharides, with sulfates (R) at various positions (commonly 4- or 6-O-sulfate on GalNAc).

Figure: Chemical structure of dermatan sulfate (chondroitin sulfate B). Dermatan sulfate differs from CS by containing L-iduronic acid (IdoA) instead of some D-glucuronic acid; its N-acetylgalactosamine is typically 4-O-sulfated.

Keratan Sulfate (KS)

Keratan sulfate consists of **β -1,3/ β -1,4 linked** repeats of galactose and N-acetylglucosamine ¹⁴. It is often sulfated on the 6-position of one or both sugars. Unlike HP/HS or CS/DS, KS is linked to core proteins via N-linked glycan chains (type II, in cartilage) or O-linked to serine/threonine (type I/III, e.g. in cornea or brain) rather than the common tetrasaccharide linkage ¹² ¹⁴. KS is abundant in **cornea, cartilage and intervertebral disc**, where it contributes to hydration and transparency.

Figure: Chemical structure of keratan sulfate (one repeating disaccharide). Keratan sulfate contains β -(1→4) linked D-galactose–D-N-acetylglucosamine disaccharides. It is often sulfated at the 6-position of GlcNAc (as shown).

Biological Roles in Human Physiology

GAGs are ubiquitous components of the **extracellular matrix (ECM)** and cell surfaces, where they critically influence tissue mechanics and cell signaling ¹⁵ ¹⁶. Their highly negative, hydrophilic chains imbibe water, providing tissues with turgidity and resilience (for example, HA gives synovial fluid its viscosity). GAGs also serve as **co-receptors and reservoirs** for bioactive proteins. For instance, heparan sulfate proteoglycans on endothelium bind chemokines and growth factors: HS–chemokine binding immobilizes chemokines on the vascular surface, guiding leukocyte rolling and extravasation ¹⁷. Similarly, HS is required for FGF growth factor signaling (by presenting FGF to its receptor). By sequestering and presenting cytokines, chemokines and morphogens, GAGs control gradients of signaling molecules ¹⁶. GAG chains also influence cell adhesion: e.g. L-selectin on leukocytes binds to endothelial HS during homing ¹⁷. In addition, specific GAG–protein interactions modulate inflammation and immunity. For example, high-molecular-weight HA is

anti-inflammatory and forms matrices that limit immune cell infiltration, whereas low-molecular-weight HA fragments can **promote inflammation and angiogenesis** ¹⁰ . The HA-versican proteoglycan matrix facilitates neutrophil and macrophage recruitment during tissue injury ¹⁸ . Overall, precise GAG structures (types and sulfation) determine how cells respond to their environment ³ ¹⁶ .

GAGs are also central to **connective tissue function**. In cartilage, aggrecan proteoglycans bearing CS/KS create a hydrated gel that cushions joints. In skin and blood vessels, dermatan sulfate on decorin/biglycan regulates collagen fibril assembly and tensile strength. In development and morphogenesis, GAGs pattern growth factor activity (e.g. HS in limb morphogenesis). Because GAGs bind many ligands, they modulate cell growth, migration, and tissue repair processes. For example, in wound healing HA matrices provide a scaffold for cell migration, while HS and CS in the ECM can bind and protect fibroblast growth factors and cytokines involved in repair ¹⁶ .

Biosynthesis and Degradation

GAG biosynthesis is a **non-template**, enzyme-driven process occurring mainly in the Golgi apparatus ¹⁹ ²⁰ . It begins in the cytosol with the production of activated sugar donors: UDP-glucuronic acid, UDP-N-acetylglucosamine, UDP-xylose, UDP-galactose, and UDP-N-acetylgalactosamine ¹⁹ . These precursors are transported into the Golgi. There, all GAGs (except HA) are assembled on a core protein: a xylose is attached to a serine residue on the protein, followed by two galactoses and a glucuronic acid, forming the tetrasaccharide linker ²¹ ²⁰ . Disaccharide units are then polymerized onto this linker by specific glycosyltransferases. During elongation, specialized **sulfotransferases** modify the chain by transferring sulfate groups from the donor PAPS to specific sugar residues (e.g. 2-O, 4-O, 6-O, and N-sulfation) ²¹ ¹⁹ . The degree and pattern of sulfation (and epimerization of glucuronic to iduronic acid) are tightly regulated and confer functional specificity to each GAG type ⁷ ¹⁴ . HA is unique: its HA synthase enzymes at the cell membrane polymerize HA directly from UDP-sugars and extrude it without further modification ⁸ ⁵ .

Once synthesized, GAGs can be cleaved and remodeled. In normal turnover, cell-surface or shed proteoglycans are taken into lysosomes and degraded by sequential **glycosidases and sulfatases**. For example, iduronidase removes terminal iduronic acid in HS/DS degradation. Failure of any lysosomal enzyme leads to accumulation of partially degraded GAGs. Such defects underlie the **mucopolysaccharidoses (MPS)**: for instance, MPS I (Hurler syndrome) arises from α -L-iduronidase deficiency, causing HS and DS buildup ²² . Accumulated GAGs in lysosomes cause cellular dysfunction, leading to multi-system disease (coarse facies, organomegaly, bone deformities, etc.) ²² . Current treatments (enzyme replacement, stem-cell transplant) aim to reduce GAG storage and improve outcomes ²² .

Clinical Significance: Disease Associations

Abnormal GAG metabolism or structure contributes to many diseases. **Genetic GAG-accumulation disorders** (mucopolysaccharidoses) illustrate how critical degradation is ²² . Beyond MPS, GAGs are implicated in chronic diseases. In **cancer**, the tumor microenvironment often has altered GAG composition. Dysregulated HS and CS in tumor stroma can promote angiogenesis, invasion, and immune evasion. A 2024 review notes that GAG alterations associate with cancer hallmarks, and recent studies suggest circulating or tissue GAG fragments may serve as early biomarkers ²³ ²⁴ . For example, elevated heparan sulfate and

specific CS disaccharides have been reported in renal and ovarian cancers, and elevated hyaluronan correlates with metastasis in breast and lung cancer ²⁵ ²⁴ . Thus, GAG profiles are being investigated for diagnostic or prognostic use ²⁴ .

GAGs also regulate **inflammation and immunity**. As noted, HS and CS bind chemokines and cytokines: altering GAG structure can modulate leukocyte trafficking and activation. In chronic inflammatory diseases, GAG degradation products (e.g. low-MW HA) can exacerbate inflammation. For instance, in arthritic joints hyaluronan breakdown fragments stimulate innate immune receptors. By contrast, dermatan sulfate has been shown to suppress pro-inflammatory cytokine activity ²⁶ . Proteoglycans like syndecan-1 or versican can accumulate in inflamed tissue and influence cell recruitment ¹⁸ . Dysregulated GAG signaling is also linked to fibrosis (excess ECM deposition) and atherosclerosis (plaque matrix GAGs bind lipoproteins). Overall, GAGs are emerging targets for modulating immune/inflammatory pathways ²⁷ ¹⁷ .

Pathogen interactions: Many microbes exploit GAGs for infection. Some viruses (e.g. papillomavirus) bind cell-surface HS to gain entry. Certain bacteria produce hyaluronan capsules (e.g. *Streptococcus pyogenes*) to mimic host HA and evade immunity ²⁸ . GAG-rich mucosal layers serve as infection barriers; their alteration can affect pathogen invasion. Thus, GAGs influence host-pathogen interactions.

Pharmaceutical and Medical Applications

Because of their biocompatibility and bioactivity, GAGs are widely used in medicine and bioengineering. The prototypical GAG drug is **heparin**: a highly sulfated form of heparan sulfate, used for >90 years as an anticoagulant to prevent thrombosis ¹³ . Low-molecular-weight heparins and synthetic heparinoids are derived from GAGs for safer anticoagulation. Hyaluronic acid has numerous clinical uses: it is injected into osteoarthritic joints to improve lubrication and relieve pain, and is a component of ophthalmic surgeries (e.g. vitreous replacement) for its viscoelasticity. HA is also used topically and in wound dressings to promote moist healing. Chondroitin sulfate is marketed as an oral supplement for osteoarthritis (often with glucosamine) based on its cartilage-protective role, though evidence of efficacy is mixed.

In **tissue engineering and drug delivery**, GAGs are key components of scaffolds and hydrogels. Because GAGs mimic natural ECM, adding them to biomaterials can improve cell adhesion and growth-factor signaling ¹¹ . For example, HA- or CS-coated hydrogels can direct stem cell differentiation and accelerate tissue regeneration ¹¹ . Researchers have engineered **GAG-functionalized biomaterials** to control morphogen presentation: one study showed that embedding heparan sulfate sequences into a scaffold enhanced BMP2-driven bone formation, whereas chondroitin sulfate motifs led to different signaling outcomes ²⁹ ³⁰ . GAG-based nanoparticles and drug carriers can exploit natural binding to growth factors or cell receptors to target therapies (e.g. heparin-coated nanocarriers binding growth factors). Modifying GAG sulfation or using heparin-mimetic polymers is being explored to tune drug release and reduce inflammation ²⁹ ¹¹ .

Finally, GAGs and proteoglycans themselves are being investigated as **therapeutic targets**. Inhibitors of hyaluronan synthesis or heparanase (the enzyme that cleaves HS) are in trials for cancer and fibrosis. Biomarkers based on GAG degradation products (e.g. urinary GAGs for MPS, serum HA for liver disease) are used clinically. Decades of research continue to uncover new GAG functions and applications, with promising advances in regenerative medicine and anti-inflammatory therapies ¹¹ ²⁴ .

Sources: Information is synthesized from recent reviews and textbooks ¹ ⁵ ¹⁶ ²³ ¹¹, including statpearls, peer-reviewed journals, and NIH sources.

¹ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹ ¹² ¹³ ¹⁴ ¹⁵ ¹⁹ ²⁰ ²¹ ²⁸ Biochemistry, Glycosaminoglycans - StatPearls - NCBI Bookshelf

<https://www.ncbi.nlm.nih.gov/books/NBK544295/>

² Category:Glycosaminoglycans - Wikipedia

<https://en.wikipedia.org/wiki/Category:Glycosaminoglycans>

³ ²⁷ Frontiers | Editorial: Proteoglycans and Glycosaminoglycan Modification in Immune Regulation and Inflammation

<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.595867/full>

¹⁰ ¹⁶ ¹⁷ ¹⁸ ²⁶ Frontiers | Regulation of Macrophage and Dendritic Cell Function by Chondroitin Sulfate in Innate to Antigen-Specific Adaptive Immunity

<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00232/full>

¹¹ Glycosaminoglycans in Tissue Engineering: A Review - PubMed

<https://pubmed.ncbi.nlm.nih.gov/33383795/>

²² A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC7062595/>

²³ ²⁴ ²⁵ The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review - United Arab Emirates - Ministry of Health and Prevention

<https://nchr.elsevierpure.com/en/publications/the-diagnostic-utility-of-glycosaminoglycans-gags-in-the-early-de/>

²⁹ ³⁰ Glycosaminoglycans Exhibit Distinct Interactions and Signaling with Bmp2 According to Their Nature and Localization by Jean Le Pennec, Olga N. Makshakova, Paola Nevola, Farah Fouladkar, Evelyne Gout, Paul Machillot, Mélanie Friedel-Arboleas, Catherine Picart, Serge Perez, Andrea Vortkamp, Romain R. Vivès, Elisa Migliorini :: SSRN

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4773964